Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Karolinska Institute’s oncology spinout Aprea Therapeutics has received a $5.7m series C extension adding to an initial $56.8m close in November 2018 that featured Karolinska Development.
MIT spinout Ginkgo Bioworks has set up Motif Ingredients with $90m in series A funding provided by investors including Louis Dreyfus Company and Fonterra.
Osage University Partners has contributed to a series A round for Vor Biopharma, an oncology drug developer based on work by Siddhartha Mukherjee at Columbia University.
Nuvaira, based on research by a then-professor at Washington University School of Medicine, has closed a $79m funding round led by US Venture Partners.
NYU and Allied Minds-founded Ram technology developer Spin Memory has unveiled deep tech-focused VC firm Abies Ventures as an investor in a $52m series B first announced late last year.